Targeting STAT3 enhances NDV‐induced immunogenic cell death in prostate cancer cells

Xueke Wang, Xiaoyan Shao, Linaer Gu, Ke Jiang, Sitong Wang, Jianhua Chen, Juemin Fang, Xianling Guo, Min Yuan, Ji Shi, Chan Ding, Songshu Meng, Qing XuJournal of Cellular and Molecular Medicine 2020 · DOI

TL;DR

This study reveals that the oncolytic virus Newcastle Disease Virus (NDV) can induce immunogenic cell death (ICD) in prostate cancer cells, a process that alerts the immune system to fight the cancer. Furthermore, inhibiting the STAT3 signaling pathway significantly boosts NDV's ability to trigger ICD, suggesting a promising combination therapy for prostate cancer.

What Problem Does This Paper Address?

Prostate cancer remains a significant health challenge, and developing effective immunotherapies is a key area of research. Oncolytic viruses, which selectively infect and kill cancer cells, are a promising class of therapeutic agents. A crucial aspect of their efficacy lies in their ability to induce "immunogenic cell death" (ICD). ICD is a form of cell death that releases "danger signals" (damage-associated molecular patterns or DAMPs) from dying cancer cells, which then alert and activate the immune system to attack the tumor. While NDV has been shown to induce ICD in other cancer types, its role in prostate cancer and the underlying mechanisms were not fully understood. This paper investigates whether NDV can induce ICD in prostate cancer cells and explores how targeting a specific signaling pathway, STAT3, might enhance this effect.

Methods

The researchers utilized a combination of in vitro and in vivo techniques:

  • Cell Culture: Human prostate cancer cell lines (DU145 and PC-3) and a control cell line (HEK293T) were used.
  • Viral Infection: Cells were infected with an oncolytic NDV strain (NDV/FMW) at various multiplicities of infection (MOI) and time points.
  • Cell Viability and Death Assays: CCK-8 assays were used to measure cell viability, while trypan blue exclusion assays and flow cytometry (Annexin V/PI staining) were employed to quantify cell death and apoptosis.
  • Immunoblotting (IB): This technique was used to detect the expression levels of various proteins, including viral proteins (HN), apoptosis markers (cleaved PARP), autophagy markers (Beclin-1), ER stress markers (p-elF2α), and key ICD markers (HSP70/90, HMGB1, STAT3, p-STAT3).
  • ELISA: Enzyme-linked immunosorbent assays were used to quantify the release of extracellular ATP and HMGB1 into the cell culture supernatant.
  • Confocal Microscopy: This technique allowed visualization of the surface expression of calreticulin (CRT) and the localization of viral proteins (HN) within infected cells.
  • Pharmacological Inhibition/Activation: Cells were pre-treated with inhibitors or activators of various cell death pathways (apoptosis, necroptosis, autophagy, ER stress) and the STAT3 pathway (using a STAT3 inhibitor, C188-9, and a STAT3 activator, IL-6) before NDV infection.
  • STAT3 Knockdown: Lentiviral vectors expressing short hairpin RNAs (shRNAs) were used to stably reduce STAT3 expression in prostate cancer cells.
  • Animal Experiments: Nude mice bearing prostate cancer cell-derived tumors were injected with either mock-treated or NDV/FMW-infected cell supernatants, or NDV/FMW itself, to assess tumor growth inhibition.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • NDV as an ICD Inducer in Prostate Cancer: The study provides the first evidence that oncolytic NDV can effectively induce immunogenic cell death in prostate cancer cells, a critical step for initiating an anti-tumor immune response.
  • STAT3 as a Modulator of NDV-Induced ICD: The research uncovers a surprising role for STAT3. While STAT3 is often implicated in cancer progression, its inhibition enhances NDV-induced ICD in prostate cancer. This is a significant finding, as it suggests a way to potentiate the anti-cancer effects of NDV.
  • Tumor-Specific Effects of STAT3 Modulation: Interestingly, the effect of STAT3 on NDV-induced ICD appears to be tumor-type dependent. The authors note that their findings in prostate cancer contradict previous work in melanoma, where STAT3 inhibition attenuated NDV-induced ICD. This highlights the complexity of cancer biology and the need for context-specific therapeutic strategies.
  • Supernatants Carry Anti-Tumor Potential: The study demonstrates that even the supernatants from NDV-infected prostate cancer cells can inhibit tumor growth in vivo, suggesting that the released DAMPs and other factors are potent enough to exert anti-cancer effects.

Key Results

  • NDV/FMW infection significantly inhibited the viability of DU145 and PC-3 prostate cancer cells and induced apoptosis.
  • NDV/FMW infection led to the expression and release of key ICD markers: calreticulin (CRT) on the cell surface, and HSP70/90 and HMGB1 in the supernatant.
  • Pharmacological inhibition of apoptosis (z-VAD-FMK) attenuated HMGB1 and HSP70/90 release, while inhibitors of autophagy (CQ), necroptosis (Necrostain-1), and ER stress (GSK2606414) boosted their release.
  • Inhibition of STAT3 signaling, either through a specific inhibitor (C188-9) or shRNA-mediated knockdown, significantly enhanced NDV/FMW-induced CRT exposure, HSP70/90 and HMGB1 release, and cell death in prostate cancer cells.
  • STAT3 inhibition also enhanced NDV replication in DU145 cells but not PC-3 cells.
  • In vivo, intratumoral injection of supernatants from NDV/FMW-infected prostate cancer cells significantly reduced tumor growth in mice.

Limitations and Future Work

  • Tumor-Origin Specificity: The contradictory findings regarding STAT3's role in NDV-induced ICD between prostate and melanoma cells highlight a limitation. The underlying mechanisms for this differential effect need further investigation.
  • Mechanism of STAT3 Action: While the study shows that STAT3 inhibition enhances NDV-induced ICD, the precise molecular mechanisms by which STAT3 influences this process in prostate cancer remain to be fully elucidated.
  • Clinical Translation: The study suggests that combining STAT3 inhibitors with oncolytic NDV could be a promising therapeutic strategy. Future work should focus on translating these findings into clinical trials, considering the existing clinical evaluation of STAT3 inhibitors.
  • ATP Release Variability: The study noted differences in ATP release between DU145 and PC-3 cells upon NDV infection, which warrants further investigation into the genetic background differences of these cell lines.

Summary updated

Abstract

Oncolytic Newcastle disease virus (NDV) induces immunogenic cell death (ICD), liberating danger-associated molecular patterns (DAMPs) that provokes defiance in neoplastic malignancy. The present study aims to investigate whether and how oncolytic NDV triggers ICD in prostate cancer cells. We show that NDV/FMW, an oncolytic NDV strain FMW, elicited the expression and release of several ICD markers, that is calreticulin (CRT), heat shock proteins (HSP70/90) and high-mobility group box 1 (HMGB1), in prostate cancer cells. Furthermore, pharmacological repression of apoptosis, necroptosis, autophagy or endoplasmic reticulum (ER) stress exerted diverse effects on the HMGB1 and HSP70/90 evacuation in NDV/FMW-infected prostate cancer cells. Moreover, ICD markers induced in prostate cancer cells upon NDV/FMW infection, were enhanced by either treatment with a STAT3 (signal transducer and activator of transcription 3) inhibitor or shRNA-mediated knockdown of STAT3. In nude mice bearing prostate cancer cell-derived tumours, the tumours injected with the supernatants of NDV/FMW-infected cells grew smaller than mock-treated tumours. These results indicate that oncolytic NDV provokes the expression of ICD makers in prostate cancer cells. Our data also suggest that a combination of inhibition of STAT3 with oncolytic NDV could boost NDV-based anti-tumour effects against prostate cancer.
BibTeX
@article{wang2020targeting,
  author = {Xueke Wang and Xiaoyan Shao and Linaer Gu and Ke Jiang and Sitong Wang and Jianhua Chen and Juemin Fang and Xianling Guo and Min Yuan and Ji Shi and Chan Ding and Songshu Meng and Qing Xu},
  title = {{Targeting STAT3 enhances NDV‐induced immunogenic cell death in prostate cancer cells}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2020},
  doi = {10.1111/jcmm.15089},
}
Figure